European Pharmaceutical Review

NOVEMBER 24, 2022

Nivolumab (Opdivo), together with chemotherapy has been recommended in the National Institute for Health and Care Excellence NICE final draft guidance for untreated HER2-negative, advanced or metastatic gastric, gastroesophageal junction (GEJ) or oesophageal adenocarcinoma where tumours express programmed death-1 receptor (PD-L1).

Chemotherapy 105

Chemotherapy Immunization 105

STAT

APRIL 10, 2024

These include oxytocin, which is used during childbirth; Rho(D) immune globulin, which helps some women during pregnancy; standard-of-care chemotherapy, pain and sedation medicines; and ADHD pills. The reasons are varied, although many remain a mystery.

Chemotherapy 140

Chemotherapy Immunization 140

STAT

MAY 8, 2024

Often overlooked or sidelined by newsmakers and policymakers, these individuals continue to confront a heightened risk of severe illness or death due to their compromised immune systems, while society largely adjusts to life with the virus.

Chemotherapy 116

Chemotherapy Immunization 116

Hospital Pharmacy Europe

AUGUST 15, 2023

A perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition with pembrolizumab significantly improves disease outcomes for patients with early-stage non-small-cell lung cancer (NSCLC), according to the findings of a trial by an international research group.

Chemotherapy 96

Chemotherapy Immunization Hospitals 96

European Pharmaceutical Review

OCTOBER 1, 2022

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. A follow-up after 12.3 months).

Chemotherapy 98

Chemotherapy Immunization Hospitals 98

European Pharmaceutical Review

MAY 17, 2023

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

Immunization 98

Immunization Chemotherapy 98

Hospital Pharmacy Europe

FEBRUARY 29, 2024

Adding an arginine-depleting agent to chemotherapy extends survival for patients with advanced non-epithelial pleural mesothelioma, a randomised controlled trial suggests. Pegargiminase-based chemotherapy was well tolerated, with no new safety signals, they added. mg/ m2) or placebo. mg/ m2) or placebo.

Chemotherapy 52

Chemotherapy Immunization Hospitals 52

Pharmaceutical Technology

NOVEMBER 23, 2022

Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. The trial enrolled 608 subjects in 14 countries, regardless of their PD-L1 expression status or histology and assessed Libtayo versus a chemotherapy of investigator's choice.

Adverse Reactions 52

Adverse Reactions Chemotherapy Immunization Labelling 52

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. New clinical data has shown a potential best-in-class next-generation antibody-drug conjugate (ADC) can offer promising response rates in extensive-stage small cell lung cancer.

Chemotherapy 96

Chemotherapy Compounding Immunization 96

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Chemotherapy 98

Chemotherapy Immunization 98

STAT

NOVEMBER 29, 2023

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation.

Chemotherapy 120

Chemotherapy Immunization FDA 120

The Checkup by Singlecare

OCTOBER 24, 2024

As an immune checkpoint inhibitor, pembrolizumab prevents cancer cells from blocking the immune system’s ability to kill off cancer cells. In that way, the immune system doesn’t attack the drug as if it were a foreign invader. These are the immune cells that fight and destroy infections and cancers.

Immunization 52

Immunization Chemotherapy FDA Dosage 52

Hospital Pharmacy Europe

OCTOBER 14, 2024

The overarching aim of this is to speed up access to messenger ribonucleic acid (mRNA) personalised cancer vaccine clinical trials for people who have been diagnosed with cancer to support treatment alongside chemotherapy, as well as prevention. Of course, we’ve also had the advent of immune checkpoint inhibitors.

Vaccines 52

Vaccines Chemotherapy Hospitals Immunization 52

Pharmafile

JANUARY 27, 2023

The antibody treatment was previously used as an additional layer of protection against the virus for those with compromised immune systems, such as those undergoing chemotherapy, or organ-transplant patients. read more

FDA 52

FDA Chemotherapy Immunization Communication 52

Hospital Pharmacy Europe

OCTOBER 2, 2024

The goal for cancer vaccines is straightforward: to harness what has been achieved for infectious diseases and their antigens to focus the immune system on eradicating cancer cells. Moving forward, exploring the factors contributing to variability in patients’ immune responses will be critical.

Vaccines 52

Vaccines Immunization Chemotherapy Hospitals 52

STAT

JUNE 6, 2023

Novocure’s study achieved its primary goal and showed a survival benefit for patients with lung cancer that progressed following initial chemotherapy.

Chemotherapy 102

Chemotherapy Immunization 102

STAT

DECEMBER 12, 2023

This approach has been around for decades but required patients to have a well-matched donor and endure a hefty dose of chemotherapy, ruling out transplant as an option for the vast majority of patients.

Chemotherapy 121

Chemotherapy Immunization 121

Pharmaceutical Technology

NOVEMBER 24, 2022

The National Institute for Health and Care Excellence (NICE) in the UK has recommended Bristol Myers Squibb ’s (BMS) nivolumab (Opdivo) plus chemotherapy as an option for patients with advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. The PD-1 protein can switch off the immune system of the body.

Chemotherapy 52

Chemotherapy Immunization 52

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Immunization 124

Immunization Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 124

European Pharmaceutical Review

AUGUST 2, 2024

The approval means TECELRA is indicated for individuals who: have received prior chemotherapy are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive have a tumour that expresses the MAGE-A4-antigen The FDA’s decision was based on results of the Phase II SPEARHEAD-1 (Cohort 1) trial.

FDA 98

FDA Chemotherapy Immunization 98

European Pharmaceutical Review

SEPTEMBER 25, 2023

The humanised IgG4 anti-PD-1 antibody is indicated for unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. The treatment is currently under review by the US FDA and the European Medicines Agency (EMA) for advanced or metastatic ESCC after prior chemotherapy.

Chemotherapy 105

Chemotherapy FDA Immunization 105

pharmaphorum

SEPTEMBER 13, 2022

Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. 1942 – Chemotherapy moves from trenches to treatment . 1942 – Chemotherapy moves from trenches to treatment . 1907 – The magic bullet of immunotherapy.

Chemotherapy 98

Chemotherapy Immunization FDA Documentation 98

Pharmaceutical Technology

NOVEMBER 13, 2022

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults.

FDA 52

FDA Chemotherapy Labelling Immunization 52

Hospital Pharmacy Europe

AUGUST 23, 2023

A human CD40 agonistic antibody targeting CD40, mitazalimab kickstarts the cancer-immunity cycle by priming and activating tumour-specific T cells. Targeting CD40 with mitazalimab has the potential to augment responses to chemotherapy.

Chemotherapy 98

Chemotherapy Immunization Hospitals FDA 98

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Immunization 105

Immunization Chemotherapy Hospitals 105

European Pharmaceutical Review

JANUARY 26, 2023

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Could CAR T therapies be manufactured in one day?

Chemotherapy 124

Chemotherapy Immunization 124

European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. After surgery, strategic combinations of radiotherapy, chemotherapy like temozolomide, and other forms of treatment, such as immunotherapy or the use of an electric field cap, are employed.

Immunization 111

Immunization Chemotherapy Packaging 111

pharmaphorum

JANUARY 3, 2023

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.

Chemotherapy 105

Chemotherapy Immunization Hospitals 105

pharmaphorum

MAY 30, 2022

“An antibody-drug conjugate is where you connect and link a chemotherapy to an antibody,” Verma said. So there’s a Trojan horse-like mechanism to deliver chemotherapy right to the cancer cell.”. While directed chemotherapy isn’t totally free of side effects, it reduces them.

Chemotherapy 116

Chemotherapy Immunization 116

pharmaphorum

NOVEMBER 29, 2022

Tecentriq is a monoclonal antibody designed to bind with PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blockings its interactions with both PD-1 and B7.1 Patients given the Tecentriq plus chemotherapy combination survived a median of 16 months after treatment, compared with 13.4

Chemotherapy 52

Chemotherapy FDA Immunization 52

European Pharmaceutical Review

MAY 12, 2023

High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.

Vaccines 98

Vaccines Immunization Chemotherapy 98

pharmaphorum

JANUARY 26, 2023

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high-dose chemotherapy and a stem cell transplant.

Chemotherapy 96

Chemotherapy Immunization Hospitals 96

pharmaphorum

OCTOBER 22, 2021

The European Commission has given a green light to Opdivo (nivolumab) with chemotherapy for previously-untreated patients with HER2-negative oesophageal, gastric and gastroesophageal junction (GEJ) cancer whose tumours express the PDL-1 biomarker with a score of five or more. months compared to 11.4 months, respectively.

Chemotherapy 105

Chemotherapy Immunization FDA 105

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunization 95

Immunization Chemotherapy FDA Pharmaceutical Companies 95

pharmaphorum

JANUARY 19, 2022

EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone.

Chemotherapy 59

Chemotherapy Immunization 59

pharmaphorum

NOVEMBER 23, 2022

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The results were published in the New England Journal of Medicine.

Chemotherapy 59

Chemotherapy Labelling Immunization Hospitals 59

European Pharmaceutical Review

JULY 12, 2022

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunization 98

Immunization Chemotherapy 98